Cansino Biologics Financials
| 688185 Stock | 61.23 0.13 0.21% |
Operating Margin 0.1212 | Profit Margin (0.96) | Return On Equity (0.14) |
Cansino | Select Account or Indicator |
Understanding current and past Cansino Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cansino Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in Cansino Biologics' assets may result in an increase in income on the income statement.
Please note, the presentation of Cansino Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cansino Biologics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cansino Biologics' management manipulating its earnings.
Cansino Biologics Stock Summary
Cansino Biologics competes with Iat Automobile, INKON Life, Kuang Chi, Tianshui Huatian, and Haima Automobile. Cansino Biologics is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE100004BM0 |
| Business Address | 401-420, Biomedical Park, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cansinotech.com |
| Phone | 86 022 5821 3600 |
You should never invest in Cansino Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cansino Stock, because this is throwing your money away. Analyzing the key information contained in Cansino Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Cansino Biologics Key Financial Ratios
Cansino Biologics' financial ratios allow both analysts and investors to convert raw data from Cansino Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of Cansino Biologics over time and compare it to other companies across industries.| Revenue | 345.18 M | ||||
| Gross Profit | (183.71 M) | ||||
| EBITDA | (829.73 M) | ||||
| Net Income | (1.45 B) | ||||
| Total Asset | 9.32 B |
Cansino Biologics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 1.8B | 6.7B | 11.9B | 11.5B | 9.3B | 6.7B | |
| Other Current Liab | 57.7M | 142.3M | 544.4M | 637.0M | 732.5M | 769.2M | |
| Other Liab | 59.8M | 174.0M | 202.0M | 222.4M | 255.7M | 134.3M | |
| Net Tangible Assets | 1.5B | 6.0B | 7.8B | 6.5B | 7.5B | 4.2B | |
| Retained Earnings | (368.1M) | (764.7M) | 1.1B | 42.7M | (1.6B) | (1.5B) | |
| Accounts Payable | 6.2M | 60.6M | 842.6M | 253.1M | 104.0M | 200.3M | |
| Cash | 202.5M | 4.4B | 5.5B | 3.4B | 2.0B | 2.5B | |
| Other Assets | 88.7M | 151.1M | 148.6M | 398.7M | 458.5M | 481.5M | |
| Long Term Debt | 130M | 90M | 40M | 878.0M | 1.1B | 1.1B | |
| Net Receivables | 15.4K | 21.6M | 157.9M | 855.5M | 636.9M | 668.7M | |
| Inventory | 16.3M | 170.5M | 875.6M | 677.8M | 350.7M | 330.2M | |
| Other Current Assets | 23.1M | 114.1M | 454.5M | 245.0M | 281.8M | 181.3M | |
| Total Liab | 314.0M | 677.2M | 3.3B | 4.2B | 4.0B | 2.1B | |
| Net Invested Capital | 1.6B | 6.2B | 9.1B | 9.2B | 7.7B | 5.5B | |
| Short Long Term Debt | 20.2M | 40.2M | 1.1B | 1.6B | 1.4B | 1.5B | |
| Total Current Assets | 794.2M | 5.4B | 9.3B | 7.7B | 5.2B | 4.6B | |
| Net Working Capital | 670.0M | 5.0B | 6.4B | 4.8B | 2.6B | 3.1B | |
| Intangible Assets | 57.2M | 72.3M | 198.3M | 258.7M | 205.6M | 138.9M |
Cansino Biologics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 21.8M | 31.6M | 59.0M | 24.1M | 35.7M | 27.1M | |
| Interest Income | 21.8M | 31.7M | 79.7M | 65.9M | 100.1M | 105.1M | |
| Interest Expense | 11.9M | 26.5M | 20.4M | 41.3M | 64.1M | 67.4M | |
| Total Revenue | 5.7M | 18.5M | 4.3B | 1.0B | 345.2M | 327.9M | |
| Gross Profit | 2.1M | 4.7M | 3.0B | (186.6M) | (876.0M) | (832.2M) | |
| Operating Income | (204.2M) | (440.3M) | 1.8B | (1.4B) | (2.1B) | (2.0B) | |
| Ebit | (217.9M) | (517.7M) | 1.8B | (1.5B) | (1.4B) | (1.3B) | |
| Research Development | 151.7M | 428.5M | 878.7M | 778.3M | 638.0M | 480.4M | |
| Ebitda | (134.3M) | (364.8M) | 2.0B | (946.3M) | (1.1B) | (1.0B) | |
| Cost Of Revenue | 147.5K | 13.8M | 1.3B | 1.2B | 1.2B | 617.7M | |
| Income Before Tax | (156.8M) | (396.6M) | 1.9B | (1.2B) | (2.0B) | (1.9B) | |
| Net Income | (156.8M) | (396.6M) | 1.9B | (909.4M) | (1.5B) | (1.4B) |
Cansino Biologics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Cansino Biologics. It measures of how well Cansino is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Cansino Biologics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Cansino had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Cansino Biologics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (8.1M) | (154.6M) | (706.4M) | (604.0M) | (214.4M) | (225.1M) | |
| Investments | (709.9M) | (60.1M) | (1.4B) | (259.8M) | 519.9M | 545.8M | |
| Change In Cash | 144.6M | 4.2B | 1.0B | (2.1B) | (774.6M) | (735.9M) | |
| Net Borrowings | (7.3M) | (22.5M) | 969.1M | 1.2B | 1.4B | 1.5B | |
| Free Cash Flow | (287.1M) | (740.2M) | 811.4M | (3.0B) | (1.9B) | (1.8B) | |
| Depreciation | 18.5M | 24.6M | 73.4M | 178.2M | 269.1M | 282.5M | |
| Other Non Cash Items | (44.5M) | (3.1M) | (31.6M) | (199.5M) | (75.8M) | (79.6M) | |
| Capital Expenditures | 116.9M | 288.3M | 1.2B | 1.1B | 659.7M | 574.7M | |
| Net Income | (156.8M) | (396.6M) | 1.9B | (909.4M) | (1.4B) | (1.4B) | |
| End Period Cash Flow | 202.0M | 4.4B | 5.5B | 3.4B | 2.3B | 2.5B | |
| Change To Netincome | (43.7M) | 5.4M | (66.6M) | 821.2M | 944.4M | 991.7M |
Cansino Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cansino Biologics's current stock value. Our valuation model uses many indicators to compare Cansino Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cansino Biologics competition to find correlations between indicators driving Cansino Biologics's intrinsic value. More Info.Cansino Biologics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cansino Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cansino Biologics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Cansino Biologics Systematic Risk
Cansino Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cansino Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Cansino Biologics correlated with the market. If Beta is less than 0 Cansino Biologics generally moves in the opposite direction as compared to the market. If Cansino Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cansino Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cansino Biologics is generally in the same direction as the market. If Beta > 1 Cansino Biologics moves generally in the same direction as, but more than the movement of the benchmark.
Cansino Biologics Total Assets Over Time
Cansino Biologics Thematic Clasifications
Cansino Biologics is part of several thematic ideas from Soft Drinks to Processed Foods. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasCansino Biologics December 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Cansino Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cansino Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cansino Biologics based on widely used predictive technical indicators. In general, we focus on analyzing Cansino Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cansino Biologics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.89 | |||
| Information Ratio | 0.139 | |||
| Maximum Drawdown | 31.84 | |||
| Value At Risk | (5.82) | |||
| Potential Upside | 6.83 |
Complementary Tools for Cansino Stock analysis
When running Cansino Biologics' price analysis, check to measure Cansino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansino Biologics is operating at the current time. Most of Cansino Biologics' value examination focuses on studying past and present price action to predict the probability of Cansino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cansino Biologics' price. Additionally, you may evaluate how the addition of Cansino Biologics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |